For B‐cell NHL, the phase 1/2 NCT00299494 trial investigated the efficacy of INO plus rituximab for R/R CD20/CD22‐positive B‐cell NHL patients; the ORR was 87% and 74%, and the 2‐year PFS rates were 68% and 42% for follicular lymphoma (FL) and DLBCL, respectively.88 The gene discussed is CD22; the disease is diffuse large B-cell lymphoma.